Completed PHASE1 INTERVENTIONAL 1-arm NCT01984658

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients

A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients

Sponsor: CytoVac A/S

Conditions Pancreatic Cancer

Interventions Alecsat

Updated 6 times since 2017 Last updated: Feb 25, 2019 Started: Oct 31, 2013 Primary completion: Jan 31, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01984658, this PHASE1 trial focuses on Pancreatic Cancer and remains completed. Sponsored by CytoVac A/S, it has been updated 6 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Terminated → Completed
Jun 2018 — Mar 2019 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CytoVac A/S

Data source: CytoVac A/S

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark